← Back to home

METASTATIC ADVANCED POORLY DIFFERENTIATED GASTROENTEROPANCREATIC NEUROENDOCRINE CARCINOMA

Clinical trials for METASTATIC ADVANCED POORLY DIFFERENTIATED GASTROENTEROPANCREATIC NEUROENDOCRINE CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new METASTATIC ADVANCED POORLY DIFFERENTIATED GASTROENTEROPANCREATIC NEUROENDOCRINE CARCINOMA trials appear

Sign up with your email to follow new studies for METASTATIC ADVANCED POORLY DIFFERENTIATED GASTROENTEROPANCREATIC NEUROENDOCRINE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug BL-M14D1 targets tough cancers in early human trial

Disease control Recruiting now

This early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delive…

Matched conditions: METASTATIC ADVANCED POORLY DIFFERENTIATED GASTROENTEROPANCREATIC NEUROENDOCRINE CARCINOMA

Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control

Last updated Jun 24, 2026 04:32 UTC

METASTATIC ADVANCED POORLY DIFFERENTIATED GASTROENTEROPANCREATIC NEUROENDOCRINE CARCINOMA

Get alerted when new METASTATIC ADVANCED POORLY DIFFERENTIATED GASTROENTEROPANCREATIC NEUROENDOCRINE CARCINOMA trials appear

New drug BL-M14D1 targets tough cancers in early human trial